Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yann-Alexandre Vano

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal for Immunotherapy of Cancer|March 19, 2022
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinomaRobert J Motzer, Toni K Choueiri, David F McDermott, et al.
The Oncologist|January 14, 2023
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell CarcinomasOmar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, et al.
BJU International|November 13, 2013
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinibBenoit Beuselinck, Yann-Alexandre Vano, Stéphane Oudard, et al.
International Journal of Cancer|May 23, 2022
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR studyYann-Alexandre Vano, Letuan Phan, Gwenaelle Gravis, et al.
British Journal of Cancer|February 6, 2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK studyBenoit Blanchet, Alicja Puszkiel, Anne Jouinot, et al.
British Journal of Cancer|January 20, 2026
Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuillard, Anne Jouinot, et al.
British Journal of Cancer|January 25, 2024
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuilard, Anne Jouinot, et al.
Cell Reports. Medicine|November 15, 2023
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomasXiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, et al.
Journal of Oncology|February 28, 2022
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter StudyCharles Vauchier, Edouard Auclin, Philippe Barthélémy, et al.
Immunity|March 1, 2022
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancerMaxime Meylan, Florent Petitprez, Etienne Becht, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|March 19, 2022
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinomaRobert J Motzer, Toni K Choueiri, David F McDermott, et al.
The Oncologist|January 14, 2023
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell CarcinomasOmar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, et al.
BJU International|November 13, 2013
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinibBenoit Beuselinck, Yann-Alexandre Vano, Stéphane Oudard, et al.
International Journal of Cancer|May 23, 2022
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR studyYann-Alexandre Vano, Letuan Phan, Gwenaelle Gravis, et al.
British Journal of Cancer|February 6, 2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK studyBenoit Blanchet, Alicja Puszkiel, Anne Jouinot, et al.
British Journal of Cancer|January 20, 2026
Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuillard, Anne Jouinot, et al.
British Journal of Cancer|January 25, 2024
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuilard, Anne Jouinot, et al.
Cell Reports. Medicine|November 15, 2023
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomasXiaofan Lu, Yann-Alexandre Vano, Xiaoping Su, et al.
Journal of Oncology|February 28, 2022
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter StudyCharles Vauchier, Edouard Auclin, Philippe Barthélémy, et al.
Immunity|March 1, 2022
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancerMaxime Meylan, Florent Petitprez, Etienne Becht, et al.
Pageof 5